HSBC Holdings
ADAP

HSBC Holdings’s Adaptimmune Therapeutics ADAP Stock Holding History

HSBC Holdings’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-26,064
Closed -$5.21K – 3007
2025
Q1 		$5.21K Hold
26,064
– – ﹤0.01% 3000
2024
Q4 		$14.3K Hold
26,064
– – ﹤0.01% 3061
2024
Q3 		$24.5K Hold
26,064
– – ﹤0.01% 2936
2024
Q2 		$25.9K Hold
26,064
– – ﹤0.01% 2861
2024
Q1 		$41.2K Sell
26,064
-440
-2% -$531 ﹤0.01% 2950
2023
Q4 		$18.8K Buy
26,504
+440
+2% +$248 ﹤0.01% 2683
2023
Q3 		$20.1K Sell
26,064
-107
-0.4% -$90 ﹤0.01% 2672
2023
Q2 		$24.2K Buy
+26,171
New +$31.2K ﹤0.01% 2516

Other funds holding ADAP

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

HSBC Holdings's ADAP Position: Q2 2025 in Review

HSBC Holdings sold out of Adaptimmune Therapeutics (ADAP) in Q2 2025, closing a stake of 26,064 shares — an estimated $5.21K sold.

HSBC Holdings first reported a position in ADAP in Q2 2023 and held it in 8 quarters. The position peaked at $41.2K in Q1 2024. 65 funds tracked by Wall St. Rank hold ADAP as of Q2 2025.

  • HSBC Holdings reported no remaining Adaptimmune Therapeutics position as of Q2 2025 after selling out during the quarter.
  • HSBC Holdings sold 26,064 Adaptimmune Therapeutics shares in Q2 2025, an estimated $5.21K.
  • HSBC Holdings first reported a position in Adaptimmune Therapeutics in Q2 2023 and held it in 8 quarters.
  • HSBC Holdings's Adaptimmune Therapeutics position peaked at $41.2K in Q1 2024.
  • 65 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q2 2025.

Based on HSBC Holdings's 13F filing for Q2 2025, filed 13 Aug 2025.